[go: up one dir, main page]

NO20082719L - Aryl-isoksazol-4-yl-oksadiazolderivater - Google Patents

Aryl-isoksazol-4-yl-oksadiazolderivater

Info

Publication number
NO20082719L
NO20082719L NO20082719A NO20082719A NO20082719L NO 20082719 L NO20082719 L NO 20082719L NO 20082719 A NO20082719 A NO 20082719A NO 20082719 A NO20082719 A NO 20082719A NO 20082719 L NO20082719 L NO 20082719L
Authority
NO
Norway
Prior art keywords
lower alkyl
halogen
heteroaryl
heterocyclyl
optionally substituted
Prior art date
Application number
NO20082719A
Other languages
English (en)
Inventor
Andreas Koblet
Bernd Buettelmann
Bo Han
Henner Knust
Andrew Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20082719L publication Critical patent/NO20082719L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Foreliggende oppfinnelse angår isoksazol-4-yl-oksadiazolderivater med formel I hvor R1 er hydrogen, halogen, aryl, heterocyklyl, heteroaryl, cyano, lavere alkyl, -(CH2)n-cykloalkyl, -(CH2)n-N(R)2, -(CH2)n-O-lavere alkyl eller -(CH2)n-OH; n er 0, 1 e ller 2 R er hydrogen eller lavere alkyl; R2 er cykloalkyl, aryl, heteroaryl eller heterocyklyl, som eventuelt er substituert med én eller flere substituenter, valgt fra gruppen bestående av halogen, cyano, nitro, lavere alkyl, lavere alkoksy, lavere alkoksy substituert med halogen, lavere alkyl substituert med halogen, C(O)O-lavere alkyl, lavere alkylsulfonyl, -NRaRb, -C(O)-NRaRb, -C(O)-heterocyklyl, benzyloksy, heterocyklyl eventuelt substituert med hydroksy, halogen eller lavere alkyl eller er heteroaryl eventuelt substituert med lavere alkyl; Ra og Rb er uavhengig hydrogen, lavere alkylsulfonyl, -C(O)H, -(CH2)n-N(R)2, -(CH2)n-O-lavere alkyl, -(CH2)n-S-lavere alkyl, -(CH2)n-S(O)2-lavere alkyl, heteroarylsulfonyl, lavere alkyl, -(CH2)n-heterocyklyl, eventuelt substituert med lavere alkyl eller er -(CH2)n-cykloalkyl, -(CH2)n-heteroaryl, -(CH2)n-OH, -(CO)-R', hvor R' er lavere alkyl, cykloalkyl eller heteroaryl; R3 er aryl eller heteroaryl, som eventuelt er substituert med halogen eller lavere alkyl substituert med halogen; så vel som farmasøytisk akseptable syreaddisjonssalter derav. Det er funnet at denne klasse forbindelser viser høy affinitet og selektivitet for GABA A ?5 reseptor bindingsseter og might være anvendelige som kognitiv enhancer eller for behandling av kognitive lidelser like Alzheimer's sykdom.
NO20082719A 2005-12-23 2008-06-13 Aryl-isoksazol-4-yl-oksadiazolderivater NO20082719L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05112956 2005-12-23
PCT/EP2006/069625 WO2007071598A1 (en) 2005-12-23 2006-12-13 Aryl-isoxazolo-4-yl-oxadiazole derivatives

Publications (1)

Publication Number Publication Date
NO20082719L true NO20082719L (no) 2008-09-16

Family

ID=37891460

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082719A NO20082719L (no) 2005-12-23 2008-06-13 Aryl-isoksazol-4-yl-oksadiazolderivater

Country Status (16)

Country Link
US (2) US7541372B2 (no)
EP (1) EP1968972B1 (no)
JP (1) JP5015172B2 (no)
KR (1) KR101121240B1 (no)
CN (1) CN101346372B (no)
AR (1) AR058719A1 (no)
AU (1) AU2006328602B2 (no)
BR (1) BRPI0620146A2 (no)
CA (1) CA2633425A1 (no)
ES (1) ES2397401T3 (no)
IL (1) IL192092A0 (no)
NO (1) NO20082719L (no)
RU (1) RU2426731C2 (no)
TW (1) TWI324602B (no)
WO (1) WO2007071598A1 (no)
ZA (1) ZA200805411B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1968973E (pt) * 2005-12-27 2011-12-09 Hoffmann La Roche Derivados de aril-isoxazol-4-il-imidazol
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
EP2137158A4 (en) * 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
KR20120102117A (ko) * 2007-12-04 2012-09-17 에프. 호프만-라 로슈 아게 아이속사졸로-피리딘 유도체
PL2291080T3 (pl) * 2008-05-14 2015-12-31 Scripps Research Inst Nowe modulatory receptorów sfingozyno-1-fosforanu
TW201033201A (en) * 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
JP2012180281A (ja) * 2009-06-29 2012-09-20 Dainippon Sumitomo Pharma Co Ltd 新規オキサジアゾール誘導体
UA110048C2 (uk) * 2011-01-28 2015-11-10 Інгібування il17 і ifn-гамма для лікування аутоімунного запалення
MX337721B (es) * 2011-09-19 2016-03-16 Suven Life Sciences Ltd Compuestos de heteroarilo como ligandos del receptor 5-ht4.
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
JP6224097B2 (ja) 2012-06-26 2017-11-01 サニオナ・エイピイエス フェニルトリアゾール誘導体及びgabaa受受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
JP6223443B2 (ja) 2012-06-26 2017-11-01 サニオナ・エイピイエス フェニルトリアゾール誘導体及びgabaa受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
ES2899906T3 (es) 2015-07-06 2022-03-15 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
ES2875562T3 (es) 2017-01-11 2021-11-10 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN114727977A (zh) 2019-11-19 2022-07-08 特维娜有限公司 化合物和化合物s1p1调节剂的制备方法
WO2021187486A1 (ja) * 2020-03-17 2021-09-23 大日本住友製薬株式会社 オキサジアゾール誘導体
BR112022023559A2 (pt) * 2020-05-21 2023-01-24 Stemsynergy Therapeutics Inc Inibidores de notch e seus usos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808663D0 (en) * 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic agents
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
EA005934B1 (ru) 2001-07-05 2005-08-25 Х. Лундбекк А/С Замещённые анилиновые пиперидины в качестве селективных антагонистов мсн
GB0128160D0 (en) * 2001-11-23 2002-01-16 Merck Sharp & Dohme Novel compounds
US20080153869A1 (en) 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
EP1812427A4 (en) * 2004-10-15 2009-10-14 Scripps Research Inst FATTY ACID AMIDE HYDROLASE OXADIAZOLE KETONE INHIBITORS
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases

Also Published As

Publication number Publication date
RU2008124198A (ru) 2010-01-27
CA2633425A1 (en) 2007-06-28
WO2007071598A1 (en) 2007-06-28
ZA200805411B (en) 2009-07-29
KR101121240B1 (ko) 2012-06-12
EP1968972A1 (en) 2008-09-17
ES2397401T3 (es) 2013-03-06
TW200732329A (en) 2007-09-01
JP2009520751A (ja) 2009-05-28
TWI324602B (en) 2010-05-11
EP1968972B1 (en) 2012-11-28
CN101346372B (zh) 2011-09-28
AU2006328602A1 (en) 2007-06-28
RU2426731C2 (ru) 2011-08-20
IL192092A0 (en) 2008-12-29
US7956074B2 (en) 2011-06-07
KR20080080213A (ko) 2008-09-02
AR058719A1 (es) 2008-02-20
BRPI0620146A2 (pt) 2011-11-01
CN101346372A (zh) 2009-01-14
US20070161686A1 (en) 2007-07-12
AU2006328602B2 (en) 2012-05-31
US20090197875A1 (en) 2009-08-06
JP5015172B2 (ja) 2012-08-29
US7541372B2 (en) 2009-06-02

Similar Documents

Publication Publication Date Title
NO20082719L (no) Aryl-isoksazol-4-yl-oksadiazolderivater
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
KR101891494B1 (ko) 신규 화합물
CA2649650C (en) Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
ES2401679T3 (es) Derivados de 6-1H-imidazo-quinazolina y de quinolinas, nuevos inhibidores de MAO y ligandos del receptor de imidazolina
MX2007014403A (es) Derivados de fenil-3-{(3-(1h-pirrol-2-il)-[1,2,4]oxadiazol-5-il]pi peridin-1-il}-metanona y compuestos relacionados como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
ATE438632T1 (de) Aryl-4-ethinylisoxazolderivate
NO20082748L (no) Aryl-isoksazol-4-yl-imidazo[1, 5-a]pyridinderivater
NO20082747L (no) Arylisoksazol-4-yl-imidazolderivater
MY136959A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
TW200736257A (en) Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives
JPWO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
KR20100016332A (ko) 신규한 디벤질아민 구조를 갖는 피리미딘 화합물 및 이것을 함유하는 의약
JP2018522047A (ja) Rorガンマモジュレータとしての新規化合物
ATE414703T1 (de) Isoxazolderivate als inverse gaba a alpha5 agonisten
TW201702226A (zh) 尿素衍生物或其醫藥上可接受鹽
JP5129138B2 (ja) 新規なベンジル(ピリジルメチル)アミン構造を有するピリミジン化合物及びこれを含有する医薬
JP6434528B2 (ja) 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
WO2006041985A3 (en) Thienopyridinone compounds and methods of treatment
CA2982824C (en) Oxindole compounds and pharmaceutical compositions thereof
WO2010004198A2 (fr) Derives anticancereux, leur preparation et leur application en therapeutique
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
CN105849101B (zh) 新的咪唑烷-2,4-二酮衍生物

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application